Liver steatosis and fibrosis in acromegaly patients with active and controlled disease: a scoping review
- 1Department of Endocrinology, Metabolic and Internal Diseases, University Clinical Hospital no. 1, Pomeranian Medical University, Szczecin, Poland
- 2Department of Hepatology and Liver Transplantology, University Clinical Hospital no. 1, Pomeranian Medical University, Szczecin, Poland
Abstract
Purpose: Excess growth hormone, as encountered in acromegaly, promotes insulin resistance and enhances adipose tissue lipolysis. This study aimed to summarize the currently available data on the prevalence of hepatic steatosis and liver fibrosis in patients with acromegaly. The secondary objective was to map the studies on the influence of treatment modalities on hepatic outcomes in this population.
Methods: This scoping review was conducted following the PRISMA-ScR guidelines. We performed a systematic literature search across two electronic databases: PubMed and Web of Science from their inception to the 4th of April 2026. In addition, articles were identified through manual searches using Google Scholar and citation tracking. Peer-reviewed original journal articles evaluating hepatic steatosis, fibrosis, and intracellular hepatic lipid (IHL) content in patients with acromegaly were included. Studies that did not utilize radiological methods and case reports were excluded. Results were synthesized narratively and summarized in tables.
Results: Twenty-one original studies were included. High heterogeneity was observed among the studies, including study models, imaging methods, patient populations, and outcomes. The data presented in this literature review reveal a pattern of lower IHL content in active acromegaly patients but a higher likelihood of liver fibrosis compared with controls. Control of acromegaly may be associated with a rise in IHL content.
Conclusions: IHL content and hepatic fibrosis in patients with acromegaly may be influenced by disease control status and treatment modalities. Further high-quality studies are required to assess the risk of liver steatosis and fibrosis in this patient population.
Related
- Comparing attenuation parameter and liver stiffness measurement using Hepatus and Fibroscan for the evaluation of steatosis and fibrosis in patients with chronic liver disease: A prospective study
- Vitamin D screening and targeted supplementation delays liver fibrosis in patients with chronic liver disease: A prospective randomized controlled trial
- Prevalence and Severity of Hepatic Steatosis and Fibrosis Across Glycemic Categories Among Patients Attending a Tertiary Care Hospital: A FibroScan-Based Cross-Sectional Study
- Comparison of Metabolic Dysfunction‐Associated Steatotic Liver Disease Between Individuals With Werner Syndrome and Those With Insulin‐Resistant Type 2 Diabetes: Hepatic Steatosis and Fibrosis Indices
- CO026 | LIVER FIBROSIS, STEATOSIS, AND SUBCLINICAL ATHEROSCLEROSIS IN PATIENTS WITH HEMOPHILIA: A CROSS-SECTIONAL STUDY
BibTeX
@article{sagan2026liver,
title = {{Liver steatosis and fibrosis in acromegaly patients with active and controlled disease: a scoping review}},
author = {Karol P. Sagan and Zuzanna Lipiec-Rzepecka and Martyna Patalong-Wójcik and Michał P. Wasilewicz and Elżbieta Andrysiak-Mamos and Anhelli Syrenicz},
journal = {Journal of Endocrinological Investigation},
year = {2026},
month = jun,
doi = {10.1007/s40618-026-02940-1},
url = {https://doi.org/10.1007/s40618-026-02940-1},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Liver steatosis and fibrosis in acromegaly patients with active and controlled disease: a scoping review
AU - Karol P. Sagan
AU - Zuzanna Lipiec-Rzepecka
AU - Martyna Patalong-Wójcik
AU - Michał P. Wasilewicz
AU - Elżbieta Andrysiak-Mamos
AU - Anhelli Syrenicz
PY - 2026
DA - 2026/06/04
JO - Journal of Endocrinological Investigation
DO - 10.1007/s40618-026-02940-1
UR - https://doi.org/10.1007/s40618-026-02940-1
AB - Purpose: Excess growth hormone, as encountered in acromegaly, promotes insulin resistance and enhances adipose tissue lipolysis. This study aimed to summarize the currently available data on the prevalence of hepatic steatosis and liver fibrosis in patients with acromegaly. The secondary objective was to map the studies on the influence of treatment modalities on hepatic outcomes in this population. Methods: This scoping review was conducted following the PRISMA-ScR guidelines. We performed a systematic literature search across two electronic databases: PubMed and Web of Science from their inception to the 4th of April 2026. In addition, articles were identified through manual searches using Google Scholar and citation tracking. Peer-reviewed original journal articles evaluating hepatic steatosis, fibrosis, and intracellular hepatic lipid (IHL) content in patients with acromegaly were included. Studies that did not utilize radiological methods and case reports were excluded. Results were synthesized narratively and summarized in tables. Results: Twenty-one original studies were included. High heterogeneity was observed among the studies, including study models, imaging methods, patient populations, and outcomes. The data presented in this literature review reveal a pattern of lower IHL content in active acromegaly patients but a higher likelihood of liver fibrosis compared with controls. Control of acromegaly may be associated with a rise in IHL content. Conclusions: IHL content and hepatic fibrosis in patients with acromegaly may be influenced by disease control status and treatment modalities. Further high-quality studies are required to assess the risk of liver steatosis and fibrosis in this patient population.
SN - 0391-4097
SN - 1720-8386
ER -